Peter joined Flagship in 2007 as an Executive-in-Residence, expanding Flagship's investment and venture creation focus on emerging Sustainability opportunities, and bringing many years of deal experience, startup venture development and industry relationships in the cleantech venture market. Peter works with several of Flagship's portfolio companies, including Ze-gen and Mascoma, where he has played roles in strategy, finance and operations. Prior to joining Flagship, Peter was President of Allegro Strategy, a consultant, advisor and interim executive with early-stage, high-tech, and cleantech startups. Peter's work has focused on early-stage venture development, and is based on a career with extensive entrepreneurial, strategy, venture development, venture deals, acquisitions, and general management experience in energy and digital media/software markets. In the past several years Peter has been an interim executive, advisor, and/or board member with a number of VC-funded early-stage companies, including cleantech startups Mascoma, Boston-Power, and Mechanology, and digital media/software ventures WorkshopLive, MetaCarta and Pyxis Mobile. Peter has founded several companies including The Human Interface Group, Inc., which was acquired by Lotus Development in 1994. Peter spent several years at Lotus and IBM in various executives roles focused on incubating, starting, and leading new knowledge management businesses, including strategy and acquisitions experience. After Lotus/IBM, Peter was a Partner at Kodiak Venture Partners, focusing on seed and early stage Internet ventures before founding Allegro Strategy to work directly with early-stage ventures and to return to energy technology opportunities. Peter has a Masters degree from the MIT Sloan School of Management with a concentration in energy economics and finance, and a BA in Environmental Design from Clark University.
Flagship Ventures is a venture capital firm focused on creating, financing and building innovative companies. Founded in 2000, Flagship manages over $600 million in early-stage funds and operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech.
The Flagship investment team consists of 10 professionals and is led by co-founders Noubar Afeyan and Ed Kania. Complementing their internal team is our extensive network of academic and industrial advisors who are actively engaged in evaluating and helping develop our new ventures. During the past two decades Flagship's principals have been involved as founders or investors in many highly successful ventures including: Adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, DataSage, Exact Sciences, Helicos Biosciences, Hypnion, IDEXX, Morphotek, PerSeptive Biosystems and TripAdvisor.
To maximize the returns to their investors, the team at Flagship Ventures combines their experience, their passion for innovation, their focus on value creation and their commitment to the success of each company's leadership team.